a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

The European Partnership for Personalised Medicine (EP PerMed) launches this Joint Transnational Call to support collaborative research projects advancing innovative and novel Cell and Gene Therapies (CGT) for personalised medicine.

This two-stage transnational call funds research projects in human health focused on the development and validation of innovative CGT approaches with a credible pathway towards clinical application.

Key features:

• Supports somatic cell therapies, gene therapies, combined cell and gene therapies, and novel biological products such as mRNA and other nucleic acid-based approaches.
• Projects must include physiologically relevant preclinical models and solid preliminary data.
• A dedicated work package on preclinical development and early Chemistry, Manufacturing and Controls (CMC) is mandatory.
• Diagnostic approaches, manufacturing methods, delivery methods and characterisation assays are eligible when clearly linked to personalised CGT.
• Research projects in all disease areas are encouraged.
• Clinical trials (Phases I-IV) are not eligible.
• Two-stage application process: pre-proposal and invited full proposal.
• Maximum project duration: 3 years.

Objective: To accelerate the development and translation of innovative personalised cell and gene therapies addressing unmet medical needs.

a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

• Only transnational projects are eligible.
• Consortia must include at least 3 independent partners from 3 different EU Member States or Associated Countries whose funding organisations participate in the call.
• Each of the three core partners must be eligible for funding from its respective funding organisation.
• Project coordinator must be eligible for funding by the corresponding regional/national funding organisation.
• Mandatory inclusion of at least one Early Career Researcher (ECR) as Principal Investigator in the consortium.
• Eligible applicants include:
  • Universities and higher education institutions.
  • Research institutes.
  • Hospitals and healthcare organisations.
  • Public health organisations.
  • SMEs.
  • Private non-profit organisations, foundations and associations.
• Strong encouragement to include partners from academia, clinical/public health sectors and private sector organisations.
• Pre-proposal stage:
  • Maximum 6 partners.
  • Up to 7 partners under specific conditions involving a third partner from the same country funded by a different funder.
• Full proposal stage:
  • Possibility to add one partner from an underrepresented country/region under the widening mechanism.
• Maximum two partners may request funding from the same funding organisation.
• Maximum one partner on own funds is allowed (excluding patient/citizen organisations).
• Patient/citizen organisations may participate as additional partners.
• Projects must be interdisciplinary and demonstrate added value of transnational collaboration.
• Projects must integrate sex and gender dimensions unless appropriately justified.
• Research must comply with ethical requirements and Responsible Research and Innovation (RRI) principles.
• Applicants must comply with applicable regional/national eligibility rules.

In case of interest, please click on 'm'interessa' and we will contact you.